Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In recent years, increasing evidence has emerged demonstrating that high-dose ascorbate bears cytotoxic effects on cancer cells in vitro and in vivo, making ascorbate a pro-oxidative drug that catalyzes hydrogen peroxide production in tissues instead of acting as a radical scavenger. This anticancer effect of ascorbate is hypoxia-inducible factor-1α- and O2-dependent. However, whether the intracellular mechanisms governing this effect are modulated by epigenetic phenomena remains unknown. We treated human melanoma cells with physiological (200 μM) or pharmacological (8 mM) ascorbate for 1 h to record the impact on DNA methyltransferase (DNMT)-activity, histone deacetylases (HDACs), and microRNA (miRNA) expression after 12 h. The results were analyzed with the MIRUMIR online tool that estimates the power of miRNA to serve as potential biomarkers to predict survival of cancer patients. FACS cell-cycle analyses showed that 8 mM ascorbate shifted BLM melanoma cells toward the sub-G1 fraction starting at 12 h after an initial primary G2/M arrest, indicative for secondary apoptosis induction. In pharmacological doses, ascorbate inhibited the DNMT activity in nuclear extracts of MeWo and BLM melanoma cells, but did not inhibit human HDAC enzymes of classes I, II, and IV. The expression of 151 miRNAs was altered 12 h after ascorbate treatment of BLM cells in physiological or pharmacological doses. Pharmacological doses up-regulated 32 miRNAs (≥4-fold) mainly involved in tumor suppression and drug resistance in our preliminary miRNA screening array. The most prominently up-regulated miRNAs correlated with a significantly increased overall survival of breast cancer or nasopharyngeal carcinoma patients of the MIRUMIR database with high expression of the respective miRNA. Our results suggest a possible epigenetic signature of pharmacological doses of ascorbate in human melanoma cells and support further pre-clinical and possibly even clinical evaluation of ascorbate for melanoma therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chen, Q., Espey, M. G., Krishna, M. C., Mitchell, J. B., Corpe, C. P., Buettner, G. R., Shacter, E., & Levine, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506390102 · Cited by 1,075 · cited 3×
“Although their original hypothesis concerning the mode of action was incorrect (encapsulation of tumors by collagen induction), in the mean time it became evident that the anticancer effects of ascorbate are principally mediated by induction of radicals (1, 4).”
BackgroundChen, Q., Espey, M. G., Sun, A. Y., Pooput, C., Kirk, K. L., Krishna, M. C., Khosh, D. B., Drisko, J., & Levine, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804226105 · Cited by 854 · cited 1×
“However, since reactive oxygen species (ROS) induce hypermethylation of the E-cadherin promoter regions in hepatoma cells (33), we hypothesized that ascorbate, a pro-oxidative radical-inducing drug in pharmacological concentrations (2, 5), might bear similar epigenetic effects on melanoma cells.”
BackgroundCameron, E., & Pauling, L. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.10.3685 · Cited by 710
Ma, Y., Chapman, J., Levine, M., Polireddy, K., Drisko, J., & Chen, Q. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007154 · Cited by 501 · cited 1×
“Yet, in recent phase I clinical trials, ascorbate failed to demonstrate a significant anticancer activity (16–19), although it enhanced chemosensitivity of ovarian cancer cells and reduced toxicity of chemotherapy (20).”
BackgroundCameron, E., & Pauling, L. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.9.4538 · Cited by 476
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy
Hoffer, L. J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S. J., Rosadiuk, K., Rousseau, C., Robitaille, L., & Miller, W. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn377 · Cited by 375
Mechanisms of Ascorbate-Induced Cytotoxicity in Pancreatic Cancer
Du, J., Martin, S. M., Levine, M., Wagner, B. A., Buettner, G. R., Wang, S.-H., Taghiyev, A. F., Du, C., Knudson, C. M., & Cullen, J. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1713 · Cited by 316
Padayatty, S. J., Sun, A. Y., Chen, Q., Espey, M. G., Drisko, J., & Levine, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011414 · Cited by 304 · cited 1×
“possible epigenetic impacts of ascorbate on melanoma cells to gain a more profound understanding of this alternative therapeutic approach widely used in complimentary medicine (91).”
BackgroundTili, E., Michaille, J.-J., Alder, H., Volinia, S., Delmas, D., Latruffe, N., & Croce, C. M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.003 · Cited by 237
Kuiper, C., Molenaar, I. G. M., Dachs, G. U., Currie, M. J., Sykes, P. H., & Vissers, M. C. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0263 · Cited by 135
Cited by
Epigenetic reprogramming of melanoma cells by vitamin C treatment
Gustafson, C. B., Yang, C., Dickson, K. M., Shao, H., Van Booven, D., Harbour, J. W., Liu, Z.-J., & Wang, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0087-z · Cited by 90
“In addition to restoring 5hmC in melanoma cells as described above, vitamin C at pharmacological doses also have been shown to inhibit the activity of DNA methyltransferases and to alter the expression of many miRNAs [34].”
Melanoma Chemoprevention: Current Status and Future Prospects
Chhabra, G., Ndiaye, M. A., Garcia‐Peterson, L. M., & Ahmad, N. (2017) · Photochemistry and Photobiology · doi:10.1111/php.12749 · Cited by 51
Russo, I., Caroppo, F., & Alaibac, M. (2015) · Cancers · doi:10.3390/cancers7030841 · Cited by 29
Metadata
- Authors
- Venturelli, S., Sinnberg, T. W., Berger, A., Noor, S., Levesque, M. P., Böcker, A., Niessner, H., Lauer, U. M., Bitzer, M., Garbe, C., & Busch, C.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2014-08-25
- Volume
- 4
- Pages
- 227-227
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1988736991
- Cited by
- 43
- References
- 11
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells. https://app.cochat.ai/papers/10.3389/fonc.2014.00227
- The paper
- Venturelli, S., Sinnberg, T. W., Berger, A., Noor, S., Levesque, M. P., Böcker, A., Niessner, H., Lauer, U. M., Bitzer, M., Garbe, C., & Busch, C. (2014). Epigenetic Impacts of Ascorbate on Human Metastatic Melanoma Cells. Frontiers in Oncology. https://doi.org/10.3389/fonc.2014.00227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.